Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study).
Mussini C, Roncaglia E, Borghi V, Rusconi S, Nozza S, Cattelan AM, Segala D, Bonfanti P, Di Biagio A, Barchi E, Focà E, Degli Antoni A, Bonora S, Francisci D, Limonta S, Antinori A, D'Ettorre G, Maggiolo F. Mussini C, et al. Among authors: barchi e. PLoS One. 2019 Sep 27;14(9):e0222650. doi: 10.1371/journal.pone.0222650. eCollection 2019. PLoS One. 2019. PMID: 31560700 Free PMC article. Clinical Trial.
CD4 cell-monitored treatment interruption in patients with a CD4 cell count > 500 x 106 cells/l.
Mussini C, Bedini A, Borghi V, Guaraldi G, Esposito R, Barchi E, Enilia R, Cozzi-Lepri A, Philips AN, Ortolani P, Bratt G, Eriksson LE, Sighinolfi L, Cossarizza A, d'Arminio Monforte A, De Luca A, Di Giambenedetto S, Antinori A; International Study Group on CD4-monitored Treatment Interruptions. Mussini C, et al. Among authors: barchi e. AIDS. 2005 Feb 18;19(3):287-94. AIDS. 2005. PMID: 15718839
Simplification to dual-therapy containing lamivudine and darunavir/ritonavir or atazanavir/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy.
Calza L, Cafaggi M, Colangeli V, Borderi M, Barchi E, Lanzafame M, Nicole' S, Degli Antoni AM, Bon I, Re MC, Viale P. Calza L, et al. Among authors: barchi e. Infect Dis (Lond). 2018 May;50(5):352-360. doi: 10.1080/23744235.2017.1410285. Epub 2017 Dec 6. Infect Dis (Lond). 2018. PMID: 29210336
Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data From the PRESTIGIO Registry.
Galli L, Parisi MR, Poli A, Menozzi M, Fiscon M, Garlassi E, Francisci D, Di Biagio A, Sterrantino G, Fornabaio C, Degli Antoni A, Angarano G, Fusco FM, D'Arminio Monforte A, Corbelli GM, Santoro MM, Zazzi M, Castagna A; PRESTIGIO Study Group. Galli L, et al. Open Forum Infect Dis. 2020 Sep 26;7(11):ofaa456. doi: 10.1093/ofid/ofaa456. eCollection 2020 Nov. Open Forum Infect Dis. 2020. PMID: 33241063 Free PMC article.
Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance.
Lori F, Malykh AG, Foli A, Maserati R, De Antoni A, Minoli L, Padrini D, Degli Antoni A, Barchi E, Jessen H, Wainberg MA, Gallo RC, Lisziewicz J. Lori F, et al. Among authors: barchi e. AIDS Res Hum Retroviruses. 1997 Nov 1;13(16):1403-9. doi: 10.1089/aid.1997.13.1403. AIDS Res Hum Retroviruses. 1997. PMID: 9359660 Clinical Trial.
Nonnucleoside reverse transcriptase inhibitor-containing regimens are associated with increased satisfaction with sexual life.
Murri R, Fantoni M, Del Borgo C, Longo B, Deiana G, Visonà R, Zambelli A, Barchi E, Orchi N, Bosco O, Wu AW. Murri R, et al. Among authors: barchi e. J Acquir Immune Defic Syndr. 2003 Dec 15;34(5):532-4. doi: 10.1097/00126334-200312150-00014. J Acquir Immune Defic Syndr. 2003. PMID: 14657766 Clinical Trial. No abstract available.
Invasive Aspergillosis in Italian AIDS patients.
Libanore M, Prini E, Mazzetti M, Barchi E, Raise E, Gritti FM, Bonazzi L, Ghinelli F. Libanore M, et al. Among authors: barchi e. Infection. 2002 Dec;30(6):341-5. doi: 10.1007/s15010-002-2033-1. Infection. 2002. PMID: 12478322
23 results